13/09/2026 First-time outcomes from the failed Ph3 EVOKE-03 study of sacituzumab govitecan-hziy+ pembro in Tx naive PD-L1 ≥50% NSCLC pts presented at WCLC'26 First-time outcomes from the failed Ph3 EVOKE-03 study of sacituzumab govitecan-hziy+ pembro in Tx naive PD-L1 ≥50% NSCLC pts presented at WCLC'26 (abstract #PL02.06; Ref) The first reported efficacy and safety outcomes from the Ph3 KEYNOTE-D46/EVOKE-03 trial of Gilead's sacituzumab govitecan-hziy (SG; TROP2 ADC) + Merck

24/08/2026 EC Expands Trodelvy + Keytruda Approval to First-Line Metastatic TNBC Across PD-L1 Status US FDA accepts Jemperli for priority review in dMMR/MSI-H rectal cancer US FDA Fast Track designation granted for ERAS-0015 in metastatic pancreatic cancer; Phase 3 trial planned EC Expands Trodelvy + Keytruda Approval to First-Line Metastatic TNBC Across PD-L1 Status (Ref) European Commission’s expanded approval of Gilead’s Trodelvy (sacituzumab govitecan-hziy; Trop-2–directe

24/06/2026 US FDA approved sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (TNBC) EU approves KEYTRUDA + Padcev as first PD-1 + ADC perioperative regimen for cisplatin-ineligible MIBC IBRANCE secures US FDA approval as the first CDK4/6 inhibitor for HR+, HER2+ metastatic breast cancer maintenance US FDA approved sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizu

23/06/2026 EC approves Trodelvy (sacituzumab govitecan) monotherapy as first-line Tx for metastatic triple-negative breast cancer patients ineligible for PD-(L)1 therapy EC approves Trodelvy (sacituzumab govitecan) monotherapy as first-line Tx for metastatic triple-negative breast cancer patients ineligible for PD-(L)1 therapy (Ref) Gilead Sciences announced that the European Commission granted marketing authorization for sacituzumab govitecan-hziy (Trodelvy; Trop-2-directed

Bladder cancer is the most common malignancy of the urinary tract. As of 2022, Bladder Cancer had an incidence of 614,298 patients worldwide, and 220,596 patients succumbed to the disease. While the therapeutic approach to it remained largely unchanged for many years, recent clinical progress has paved the way towards a novel era of diagnosis and management of the disease, with several special designations and two very recent approvals by the US FDA. In December 2023, the FD